The cancer cachexia syndrome. The influence of treatment on selected clinical and biochemical parameters. Preliminary report;Zespół wyniszczenia nowotworowego. Wpływ leczenia na wybrane parametry kliniczne i biochemiczne. Doniesienie wstȩpne

Polska Medycyna Paliatywna

Volumn 4, Issue 1, 2005, Pages 11-16

  Ba̧czyk, Maciej ^a,b   Gorzelińska, Lidia ^a   Łuczak, Jacek ^a   Sowiński, Jerzy ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b Katedra i Klinika Endokrynologii   (Poland)

Author keywords

Cancer cachexia; Cortisol; Cytokines; Progestins

Indexed keywords

GLUCOSE; HYDROCORTISONE; INSULIN; INTERLEUKIN 6; LIOTHYRONINE; PROGESTERONE DERIVATIVE; SOMATOMEDIN C; THYROXINE; TUMOR NECROSIS FACTOR ALPHA;

ANOREXIA; APPETITE; ARTICLE; CACHEXIA; CANCER CACHEXIA SYNDROME; DEPRESSION; DISEASE SEVERITY; DRUG INDICATION; GLUCONEOGENESIS; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; LIPOLYSIS; MEAL; MENTAL HEALTH; MUSCLE MASS; POSTPRANDIAL STATE; PROTEIN DEGRADATION; SYMPTOMATOLOGY; WEIGHT REDUCTION;

EID: 21844440351     PISSN: 1644115X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Wojtukiewicz M.Z., Rybałtowski M. Zespół wyniszczenia nowotworowego. Leczenie wspomagaja̧ce 2003; 1: 2-16.
2. Inui A. Cancer anorexia-cachexia syndrome: current issues in research and management. Cancer J. Clin. 2002; 52: 5272-5291.
3. Laviano A., Meguid M., Rossi-Fanelli F. Cancer anorexia: clinical implications, pathogenesis and treatment. Lancet Oncol. 2003; 4: 689-694.
4. Strasser F, Bruera E.D. Update on anorexia and cachexia. Hematology/Oncology Clin. North Am. 2002; 16: 589-617.
5. Puccio M., Nathason L. The cancer cachexia syndrome. Semin. Oncol. 1997; 24: 277-287.
6. Tisdale M.J. Cancer cachexia: metabolic alternations and clinical manifestations. Nutrition 1997; 13: 1-7.
7. Bing C., Taylor S., Tisdale M.J., Williams G. Cachexia in MAC16 adenocarcinoma; suppression of hunger despite normal regulation of leptin, insulin and hypothalamic neuropeptide Y. J. Neurochem. 2001; 79: 1004-1012.
8. Tommey D., Redmond H.P, Bouchier-Hayes D. Mechanism mediating cancer cachexia. Cancer 1995; 76: 2419-2426.
9. Mantovani G., Maccio A., Massa E., Madeddu C. Managing cancer-related anorexia/cachexia. Drugs 2001; 61: 499-514.
10. Landowski J. Depresja jako przewlekły stres. Dyskusje o Depresji 2001; 17: 2-6.
11. Yoshikawa T., Noguchi Y., Satoh S. i wsp. Insuline resistance and the alterations of glucose transporter-4 in adipose cells from cachectic tumor bearing rats. J. Parenter. Enteral. Nutr. 1997; 21 (6): 347-349.
12. Laviano A., Meguid M.M., Yang Z.J. i wsp. Cracking the riddle of cancer anorexia. Nutrition 1996; 12: 706-710.
13. Schein P.S., Kisner D., Haller D. i wsp. Cachexia of malignancy. Potential role of insuline in nutritional management. Cancer 1997; 43: 2070-2076.
14. Hasselgren P., Wray C., Mammen J. Molecular regulation of muscle cachexia: it may be more than the proteasome. Biochem. Biophys. Res. Commun. 2002; 290: 1-10.
15. Coletti D., Yang E., Marazzi G., Sassoon D. TNF-α inhibits skeletal myogenesis through a PW1-dependent pathway by recruitment of caspase pathways. EMBO J. 2002; 21: 631-642.
16. Mitch W.E., Price S.R. Trancription factors and muscle cachexia: is there a therapeutic target? Lancet 2001; 357: 734-735.
17. Lorite M.J., Thompson M.G., Drake L.G. i wsp. Mechanism of muscle protein degradation induced by a cancer cachectic factor. Br. J. Cancer 1998; 78: 850-856.
18. Maltoni M., Fabbri L., Nanni O. i wsp. Serum levels of tumor necrosis factor alpha and other cytokines do not correlate with weight loss and anorexia in cancer patients. Support Care Cancer 1997; 5: 130-135.
19. Loprinzi C.L., Kugler J.W., Sloan J.A. i wsp. Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. J. Clin. Oncol. 1999; 17: 3299-3306.
20. Tchekmedyian N.S. Costs and benefits of nutrition support in cancer. Oncology 1995; 9 (11 supl.): 79-84.